Multicenter, randomized, parallel group, phase II study to establish the efficacy and safety of CBP501, cisplatin, and nivolumab for I third-line treatment of patients with exocrine pancreatic cancer and WBC <10,000/mm3 Article

Full Text via DOI: 10.1016/j.annonc.2023.09.2574 Web of Science: 001087480202298

Cited authors

  • Enzler T, Nguyen A, Misleh J, Cline VJ, Johns ME, Shumway N, Paulson AS, Siegel R, Larson T, Messersmith W, Richards D, Chaves J, Pierce E, Zalupski M, Sahai V, Orr D, Kawabe T, Ruste SA, Haun A

Publication date

  • 2023

Published in

International Standard Serial Number (ISSN)

  • 0923-7534

Number of pages

  • 1

Start page

  • S900

End page

  • S900


  • 34